What is the effect of taking Adagrasib for three months?

Adagrasib is an oral small molecule targeted inhibitor targeting the KRAS G12C mutation. It is mainly used to treat non-small cell lung cancer (NSCLC) and other malignant tumors carrying this mutation. It continuously inhibits the activity of mutated proteins, thereby blocking tumor cell proliferation signaling pathways, achieving the effect of controlling the disease and shrinking tumors. Many patients are concerned when using this medicine: Will the effect be obvious after taking it for three months? Clinical research and treatment experience give clear references.

Judging from clinical trial data, the initial efficacy of adagrasib generally begins to appear 6-8 weeks after treatment, including tumor shrinkage, tumor marker decline and other reactions. After three months of continuous use (about 12 weeks), most patients can achieve disease control (including partial remission or stable disease). For example, in a study called KRYSTAL-1, adagrasib was tested in KRAS Patients with advanced NSCLC with G12C mutations showed an objective response rate approaching 43% ( span>ORR), and the disease control rate (DCR) is as high as 80% or more. This means that in most patients, their tumors will at least no longer progress after three months of continuous treatment.

For some sensitive patients, after three months, they may see significant tumor shrinkage, improvement in clinical symptoms (such as cough, chest tightness, pain), and improvement in quality of life. However, the speed and degree of efficacy vary from person to person and are also related to the patient's overall health status, mutation load, and whether it is combined with other treatments. In addition, some patients may experience mild to moderate adverse reactions in the early stages of taking the drug, such as diarrhea, nausea, fatigue, etc., but most of them can be relieved under the guidance of a doctor without affecting the sustained release of the therapeutic effect.

It is worth noting that as a targeted maintenance treatment drug, the treatment course of adagrasib is often more than three months. Even if a positive response occurs after three months, patients need to continue taking the medication to maintain efficacy and prevent recurrence. Therefore, after taking adagrasib for three months, patients should promptly review imaging and tumor indicators, evaluate the efficacy, and decide under the guidance of a doctor whether to continue using the drug at the original dose or combine it with other regimens to ensure long-term benefits. In general, the three-month medication cycle of adagrasib is usually an important evaluation node, and many patients can initially see the therapeutic effect at this time, and even lay the foundation for further long-term relief.

References：https://www.krazati.com/